RankAlpha logo
Back to Rankings

VTRS

ViatrisA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The Q1 print and guidance reaffirmation suggest Viatris can still deliver operating leverage, while Greater China and branded-drug strength provide near-term support. The meloxicam NDA adds a discrete pipeline readout that could widen the valuation range if it clears FDA review.
Posture
Constructive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-26.
What can break
Fast-acting meloxicam is still a binary FDA review until the Dec. 27, 2026 PDUFA date.
Momentum
90
Value
65
Sentiment
50
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $15.80 · Bull $19.00 · Bear $12.50Analysis 2026-05-28; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-28 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-26

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions

Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $20.33
Why
Momentum90 · Δ7d +0.9
Value65 · Δ7d -0.1
Sentiment50 · Δ7d +2.3
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • 3 setup hits (3d) with net bullish as of 2026-10-26.
  • • News driver: Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies.
  • • Value remains the lead driver in the composite, 7D delta -0.1.

Contradictions & invalidation

  • • Fast-acting meloxicam is still a binary FDA review until the Dec. 27, 2026 PDUFA date.
  • • The May 2026 CFO transition adds a small but real near-term execution/continuity risk.
  • • Management held guidance rather than raising it, the packet’s median target is below the 16.29 anchor, and core generics/margin pressure can still offset launch wins.

Catalyst clock

2026-05-07

Q1 2026 beat and guidance reaffirmation

Lead driver: Value · See fundamentals
Momentum
90
8% active weight
Current posture
7d trendFlat
Δ7d
+0.9
Δ21d
+11.9
Value
65
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.9
Sentiment
50
45% active weight
Current posture
7d trendImproving
Δ7d
+2.3
Δ21d
-9.3
Why this grade

Composite grade A. Momentum 90.4 / Value 65.0 / Sentiment 49.7

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-28. Scenario method

B+
Bull case
20%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-05-28 · RankAlpha Sentiment Codex
Most likely
B
Base case
55%
Probability
Target price
$15.80
Analysis reference price unavailable
Analysis 2026-05-28 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-05-28 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$21.01B
Beta
0.78
Shares Out
1.15B
P/E (TTM) · Derived
-6.1
P/S (TTM)
1.01
P/FCF (TTM)
13.63
Rev YoY
+5.0%
EPS YoY
+2517.9%
Gross Margin
+39.6%
Op Margin
+9.7%
Net Debt
$13.25B
Current Ratio
1.49
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data